Daraxonrasib delivered a median overall survival of 13.2 months versus 6.7 months with standard chemotherapy in previously ...

Summer feeding should be paused because this is a time when natural food sources such as caterpillars, bugs and flies, are ...

By Sriparna Roy April 13 (Reuters) - Revolution Medicines' experimental oral drug helped patients with pancreatic cancer live ...

In a difficult disease, Revolution Medicines achieved what the pancreatic cancer community has long desired: a significant improvement in survival. The Phase 3 results will support global regulatory ...

Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib ...

Almost 100% of patients with recurrent/metastatic endometrial cancer benefited from an investigational bispecific antibody ...

Trastuzumab deruxtecan reduces the risk of disease progression and death over chemotherapy in gastric or gastroesophageal junction cancer patients.

Grant is an M.D./M.B.A. student at Harvard Medical School and Harvard Business School, a researcher at Boston Children’s ...

Daraxonrasib, a new pancreatic cancer drug, cut the risk of death by 60% in a Phase 3 trial. A doctor explains how it works, ...

A chemotherapy-free regimen for advanced/recurrent endometrial cancer achieved durable disease control in a substantial ...

A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) ...

The Pancreatic Cancer Action Network (PanCAN), the leading organization dedicated to advancing progress against pancreatic ...